Novacyt publishes its monthly liquidity contract data

Novacyt SA, a molecular diagnostics company, has released its monthly balance sheet for September 2025 for shares traded under its liquidity agreement with Invest Securities SA. During this period, 16,600 ordinary shares were purchased and 18,216 sold, with prices ranging from €0.44 to €0.49.

The liquidity agreement, governed by French law, allows Invest Securities to manage share purchases for Novacyt within certain limits set by shareholders. At the end of September, Novacyt held 104,912 treasury shares.

Novacyt, listed on the AIM and Euronext Growth markets, has a total of 70,626,248 shares. This information is essential for shareholders, particularly when assessing their stake in the company.